Walden Biosciences
Dr. Alex Duncan is a seasoned antibody research scientist and business leader with over 20 years of experience in the biopharmaceutical industry creating safe and effective medicines for patients in all major therapy areas.
Previously, Dr. Duncan was the Chief Technology Officer and Head of Research at Agenus where he was responsible for closely aligning research and manufacturing technology to deliver manufacturable and innovative development candidates across different drug modalities. In his prior role, Dr. Duncan directed the modernization and optimization of Agenus’ technical platforms and was responsible for all manufacturing and quality systems including those relating to Prophage.
Prior to joining Agenus in January 2015, Dr. Duncan was Managing Director at Actigen, a company focused on the development of immunomodulatory antibody compounds. Before that, he served as Chief Scientific Officer and Head of Research & Development at Affitech A/S (Denmark) and was a member of the AstraZeneca Discovery senior management team, where he served as Senior Vice President Biopharmaceuticals and led the Cambridge UK Discovery site, previously Cambridge Antibody Technology (CAT). Prior to its acquisition by AstraZeneca, Dr. Duncan was Senior Vice President Drug Discovery at CAT, where he built a world-class antibody discovery capability. Technology developed by CAT was used to create adalimumab, the first fully human antibody blockbuster drug known commercially as Humira.
Dr. Duncan earned his Ph.D. in Dr. Sir Greg Winter’s laboratory at the MRC Laboratory of Molecular Biology, University of Cambridge and held post-doctoral positions at the University of California San Diego.
This person is not in any offices
Walden Biosciences
Walden Biosciences is a biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease. We are developing breakthrough medicines targeted directly to the kidney and will be successful through our comprehensive knowledge and understanding of novel kidney-specific biological pathways and our team’s track record in drug discovery. Our goal is to transform the treatment of kidney disease by reversing its progression, enabling and inspiring patients to resume their normal lives. Our culture is collaborative and entrepreneurial, and our team is dynamic and driven by data and innovation. We want to make the best decisions with the best available information, lead by example, and bring transformative medicines to patients in need. Walden is based in the heart of Cambridge, MA between Harvard, Massachusetts Institute of Technology (MIT), and Massachusetts General Hospital.